References
1. Pinto C, Lorca-Garcia C, Berenguer B, et al. Bleomycin-induced flagellate erythema after venous malformation sclerosis-Case report and brief review. Pediatr Dermatol, 2018. 35(1): p. e5-e8.
2. Stefanou A, Siderov J. Medical errors. Dosage nomenclature of bleomycin needs to be standardised to avoid errors. BMJ, 2001. 322(7299): p. 1423-4.
3. U.S. Food and Drug Adminstration. Bleomycin sulfate instruction. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050443 [2010, accessed 5 August 2021].
4. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol, 2001. 19(6): p. 1629-40.
5. Loehrer PS, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol, 1995. 13(2): p. 470-6.
6. Culine S, Kramar A, Theodore C, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol, 2008. 26(3): p. 421-7.
7. Azambuja E, Fleck JF, Batista RG, et al. Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther, 2005. 18(5): p. 363-6.
8. Tobwala S, Fan W, Stoeger T, et al. N-acetylcysteine amide, a thiol antioxidant, prevents bleomycin-induced toxicity in human alveolar basal epithelial cells (A549). Free Radic Res, 2013. 47(9): p. 740-9.
9. Shahbaz M, Kamran SH, Anwar R. Amelioration of Bleomycin and Methotrexate-Induced Pulmonary Toxicity by Serratiopeptidase and Fisetin. Nutr Cancer, 2020: p. 1-10.
10. Sakamoto K, Ito S, Hashimoto N, et al. Pirfenidone as salvage treatment for refractory bleomycin-induced lung injury: a case report of seminoma. BMC Cancer, 2017. 17(1): p. 526.
11. White DA, Stover DE. Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids. Chest, 1984. 86(5): p. 723-8.
12. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med, 2015. 372(17): p. 1598-607.
13. Straus DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood, 2018. 132(10): p. 1013-1021.
14. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med, 2016. 374(25): p. 2419-29.
Figure 1 Schematic historical and current information from the episode of care